Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Net Income (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Net Income for 13 consecutive years, with -$4.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 103.76% to -$4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.6 million, a 27.09% decrease, with the full-year FY2025 number at -$13.6 million, down 27.09% from a year prior.
  • Net Income was -$4.7 million for Q4 2025 at Ekso Bionics Holdings, down from -$1.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$1.4 million in Q3 2025 to a low of -$4.7 million in Q4 2025.
  • A 5-year average of -$3.5 million and a median of -$3.4 million in 2021 define the central range for Net Income.
  • Biggest YoY gain for Net Income was 47.76% in 2025; the steepest drop was 103.76% in 2025.
  • Ekso Bionics Holdings' Net Income stood at -$4.6 million in 2021, then rose by 1.87% to -$4.5 million in 2022, then grew by 21.92% to -$3.5 million in 2023, then skyrocketed by 34.88% to -$2.3 million in 2024, then crashed by 103.76% to -$4.7 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Net Income are -$4.7 million (Q4 2025), -$1.4 million (Q3 2025), and -$4.0 million (Q2 2025).